.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,300,669

« Back to Dashboard

Claims for Patent: 7,300,669

Title:Fluticasone lotion having improved vasoconstrictor activity
Abstract:A fluticasone lotion having improved vasoconstrictor and anti-inflammatory activity and higher than expected potency. The fluticasone lotion contains 0.05 weight percent fluticasone propionate and an oil-in-water vehicle that includes excipients. The fluticasone lotion is unexpectedly efficacious while exhibiting an improved safety profile.
Inventor(s): Dow; Gordon J. (Petaluma, CA), Johnson; Keith Arthur (Durham, NC), Kelly; Frances Furr (Durham, NC), Lathrop; Robert William (Fort Collins, CO), Rajagopalan; Rukmini (Durham, NC)
Assignee: Altana Inc. (Melville, NY)
Application Number:10/800,840
Patent Claims: 1. A topical lotion, comprising: about 0.005 to 1.0 wt. % fluticasone, or a pharmaceutically acceptable salt or ester thereof; about 4.0 to 6.0 wt. % of a C.sub.14-C.sub.20 fatty alcohol or mixtures thereof; about 1.0 to 5.0 wt. % of at least one first skin conditioning agent; about 5.0 to 15.0 wt. % propylene glycol; and the balance in water; wherein the lotion is free of mineral oil and white soft paraffin, and wherein the lotion causes more vasoconstriction when applied to living human skin than does application of a cream containing mineral oil or soft white paraffin, or both, the cream containing the same amount of the fluticasone or the pharmaceutically acceptable salt or ester thereof.

2. The lotion of claim 1 further comprising about 0.25 to 3.0 wt. % of at least one surfactant.

3. The lotion of claim 1 further comprising about 0.5 to 2.0 wt. % of at least one surfactant.

4. The lotion of claim 1 further comprising dimethicone in an amount up to about 5.0 wt. %.

5. The lotion of claim 4 further comprising about 0.5 to 3.0 wt. % of dimethicone.

6. The lotion of claim 4 further comprising about 1.0 to 2.0 wt. % of dimethicone.

7. The lotion of claim 5 wherein said C.sub.14-C.sub.20 fatty alcohol or mixtures thereof is cetostearyl alcohol.

8. The lotion of claim 7 wherein said first skin conditioning agent is isopropyl myristate.

9. The lotion of claim 8 further comprising about 0.25 to 3.0 wt. % of at least one surfactant.

10. The lotion of claim 8 further comprising about 0.5 to 2.0 wt. % of at least one surfactant.

11. The lotion of claim 10 wherein said surfactant is Cetomacrogol.

12. The lotion of claim 11 further comprising one or more buffers.

13. The lotion of claim 12 further comprising one or more preservatives.

14. The lotion of claim 13 wherein said fluticasone, or a pharmaceutically acceptable salt or ester thereof is fluticasone propionate.

15. The lotion of claim 14 wherein said one or more buffer is selected from the group consisting of: sodium citrate and citric acid.

16. The lotion of claim 15 wherein said one or more preservative is selected from the group consisting of: imidurea, methylparaben, and propylparaben.

17. A method of treating a skin condition treatable by fluticasone, comprising topically administering to a patient in need thereof a lotion according to claim 14.

18. The method of claim 15 wherein said skin condition is selected from the group consisting of: corticosteroid-responsive dermatosis, atopic dermatitis, inflammation, eczema, erythema, papulation, scaling, erosion, oozing, crusting and pruritis.

19. A topical lotion, comprising: about 0.05 wt. % fluticasone, or a pharmaceutically acceptable salt or ester thereof; about 4.0 to 6.0 wt. % of cetostearyl alcohol; about 1.0 to 2.0 wt. % of isopropyl myristate; about 5.0 to 15.0 wt. % propylene glycol; about 0.5 to 3.0 wt. % of dimethicone; about 0.25 to 3.0 wt. % of at least one surfactant; and the balance in water; wherein the lotion is free of mineral oil and white soft paraffin, and wherein the lotion causes more vasoconstriction when applied to living human skin than does application of a cream containing mineral oil or soft white paraffin, or both, the cream containing the same amount of the fluticasone or the pharmaceutically acceptable salt or ester thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc